On December 16, 2024, the federal judge overseeing the Valsartan litigation confirmed the selection of five cases for the second set of bellwether trials. These trials are part of the multidistrict litigation (MDL) against the manufacturers of Valsartan, specifically addressing the harmful effects of NDMA contamination in the medication. MDL 2875 includes individuals who were harmed by the contaminated drug, and these bellwether trials will serve as important test cases, offering insights into how other lawsuits in the MDL may be resolved. As such, the outcomes of these trials hold significant implications for all plaintiffs involved in the litigation.
[fluentform id=”15″]
